FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3 -mutated acute myeloid leukemia (AML) patients.
Gong HeErika BelmontTheodore KarrisonWendy StockJames L LaBelleSatyajit KosuriRichard A LarsonJustin P KlinePeter A RiedellMariam NawasMichael R BishopHongtao LiuPublished in: Annals of translational medicine (2024)
When adjusting for conditioning regimen and donor status, there was a significant improvement in DFS and OS for patients who received FLT3i maintenance therapy compared to those who did not. Randomized prospective studies may provide more insight.
Keyphrases
- acute myeloid leukemia
- stem cell transplantation
- high dose
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- newly diagnosed
- ejection fraction
- tyrosine kinase
- open label
- prognostic factors
- peritoneal dialysis
- double blind
- bone marrow
- phase iii
- placebo controlled
- patient reported outcomes
- phase ii
- case control